These findings from previous real-world studies and our study re-affirm effectiveness of ALK TKIs in practice and further confirm the superior benefit of alectinib over crizotinib and over chemotherapy in the first-line treatment setting, supporting the shift to alectinib as the standard of care for patients with advanced ALK-positive NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.